Related Experiment Videos
The future of plasma derivatives.
1Department of Plasma Proteins, CLB, Sanquin Blood Supply Foundation, Amsterdam, The Netherlands. k_mertens@clb.nl
Summary
Recombinant DNA technology promised unlimited plasma proteins, but high costs and development times limited therapeutic applications. Plasma derivatives now offer a safe and cost-effective alternative, enabling exploration of unused therapeutic proteins.
Area of Science:
- Biotechnology
- Pharmaceutical Science
- Hematology
Background:
- Recombinant DNA technology offered a vision of abundant recombinant plasma proteins.
- The economic and developmental challenges of biotechnological pharmaceuticals were underestimated.
- Limited therapeutic plasma proteins have been approved since the 1980s.
Purpose of the Study:
- To re-evaluate plasma derivatives in light of current biotechnological limitations.
- To highlight the safety and cost-effectiveness of plasma-derived pharmaceuticals.
- To explore the potential of underutilized plasma proteins for therapeutic applications.
Main Methods:
- Comparative analysis of recombinant versus plasma-derived protein production.
- Assessment of safety standards for plasma derivatives.
- Economic evaluation of multi-protein production from human blood.
Main Results:
- Biotechnological pharmaceutical development faced underestimated costs and timelines.
- Plasma derivatives can now achieve safety standards comparable to recombinant products.
- Human blood allows cost-effective production of multiple pharmaceutical proteins simultaneously.
Conclusions:
- Plasma derivatives represent a viable and safe alternative to recombinant proteins.
- The cost-efficiency of producing multiple proteins from blood warrants further investigation.
- Numerous unused plasma proteins hold therapeutic potential that can be explored.